Suppr超能文献

实验室标志物与生殖细胞肿瘤。

Laboratory markers and germ cell tumors.

作者信息

von Eyben Finn Edler

机构信息

Center of Tobacco Control Research, Gardesmuttevej 30, DK-5210 Odense NV, Denmark.

出版信息

Crit Rev Clin Lab Sci. 2003 Aug;40(4):377-427. doi: 10.1080/10408360390247814.

Abstract

The International Germ Cell Consensus Classification (IGCCC) of testicular germ cell tumors (TGCT) in 1997 included three serum tumor markers, serum lactate dehydrogenase catalytic concentration (S-LD), serum alpha fetoprotein concentration (S-AFP), and serum human chorionic gonadotropin concentration (S-hCG). The recommendation should be implemented for all patients with TGCT and is also useful for patients with ovarian and extragonadal germ cell tumors. A fourth serum tumor marker for TGCT, S-LD isoenzyme 1 (S-LD-1), is also relevant for TGCT. Patients with seminoma have a raised S-LD-1 more often than a raised S-AFP and S-hCG, whereas patients with nonseminoma have a raised S-AFP more often than a raised S-LD-1 and S-hCG. A new model combining IGCCC and S-LD-1 predicts survival better than previous staging systems. LD-1 is related to a characteristic chromosomal abnormality in all types of TGCT, a high copy number of chromosome 12p. In contrast, AFP and hCG are found mainly in nonseminomatous germ cell tumors and they related to the histologic differentiation of the tumors. The different biologic background for the serum tumor markers may contribute to the difference in their clinical behavior.

摘要

1997年的睾丸生殖细胞肿瘤(TGCT)国际生殖细胞共识分类(IGCCC)纳入了三种血清肿瘤标志物,即血清乳酸脱氢酶催化浓度(S-LD)、血清甲胎蛋白浓度(S-AFP)和血清人绒毛膜促性腺激素浓度(S-hCG)。该建议应适用于所有TGCT患者,对卵巢和性腺外生殖细胞肿瘤患者也有用。TGCT的第四种血清肿瘤标志物,即S-LD同工酶1(S-LD-1),对TGCT也有意义。精原细胞瘤患者S-LD-1升高的情况比S-AFP和S-hCG升高更为常见,而非精原细胞瘤患者S-AFP升高的情况比S-LD-1和S-hCG升高更为常见。一种将IGCCC和S-LD-1相结合的新模型比以往的分期系统能更好地预测生存率。LD-1与所有类型TGCT中的一种特征性染色体异常有关,即12号染色体短臂的高拷贝数。相比之下,AFP和hCG主要见于非精原性生殖细胞肿瘤,它们与肿瘤的组织学分化有关。血清肿瘤标志物不同的生物学背景可能导致它们临床行为的差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验